{
    "clinical_study": {
        "@rank": "100685", 
        "arm_group": [
            {
                "arm_group_label": "Micronized trans-resveratrol", 
                "arm_group_type": "Active Comparator", 
                "description": "Micronized trans-resveratrol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether micronized trans-resveratrol improves\n      clinical (excessive hair, menstrual cycle), endocrine (androgens)and metabolic (lipids,\n      markers of systemic inflammation) in women with polycystic ovary syndrome (PCOS)."
        }, 
        "brief_title": "Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Polycystic Ovary Syndrome (PCOS)", 
        "condition_browse": {
            "mesh_term": "Polycystic Ovary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  PCO - Androgen Excess Society criteria: hyperandrogenism (hirsutism) /\n             hyperandrogenemia (testosterone >70ng/dl) and/or oligomenorrhea (<8 spontaneous\n             menses per year) and/or polycystic ovarian morphology on ultrasound\n\n          -  Normal prolactin, TSH, 17-OH progesterone\n\n          -  No evidence of androgen producing malignancy, Cushing's syndrome or acromegaly\n\n          -  Age 18-40\n\n        Exclusion Criteria:\n\n          -  Use of oral contraceptives and/or other steroid hormones 3 months prior to the study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720459", 
            "org_study_id": "681/10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Micronized trans-resveratrol", 
                "intervention_name": "Micronized trans-resveratrol", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Micronized trans-resveratrol 500 (Rev Genetics LLC - Miami, FL, USA)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Resveratrol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 1, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Poznan", 
                    "country": "Poland", 
                    "zip": "60-535"
                }, 
                "name": "Poznan University of Medical Sciences"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Micronized Trans-resveratrol Treatment on Clinical, Endocrine, Metabolic and Biochemical Parameters of Women With Polycystic Ovary Syndrome: Placebo-controlled Randomized Single-blind Study", 
        "overall_contact": {
            "email": "bbeata48@gmail.com", 
            "last_name": "Beata Banaszewska, MD PhD", 
            "phone": "+48 61 8419412"
        }, 
        "overall_contact_backup": {
            "email": "rspaczynski@yahoo.com", 
            "last_name": "Robert Z Spaczynski, MD PhD", 
            "phone": "+48 61 8419412"
        }, 
        "overall_official": [
            {
                "affiliation": "Poznan University of Medical Sciences", 
                "last_name": "Leszek A Pawelczyk, MD PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of California, Davis", 
                "last_name": "Antoni J Duleba, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Poland: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "testosterone serum concentration", 
            "safety_issue": "No", 
            "time_frame": "3 month therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720459"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Poznan University of Medical Sciences", 
            "investigator_full_name": "Beata Banaszewska", 
            "investigator_title": "MD PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Poznan University of Medical Sciences", 
        "sponsors": {
            "collaborator": {
                "agency": "University of California, Davis", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Poznan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}